Increased Cell Wall Teichoic Acid Production and D-alanylation Are Common Phenotypes among Daptomycin-Resistant Methicillin-Resistant Staphylococcus aureus (MRSA) Clinical Isolates

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Bertsche, Ute ^a   Yang, Soo Jin ^b,c   Kuehner, Daniel ^a,d   Wanner, Stefanie ^a   Mishra, Nagendra N ^b   Roth, Tobias ^a   Nega, Mulugeta ^a   Schneider, Alexander ^a   Mayer, Christoph ^a   Grau, Timo ^a   Bayer, Arnold S ^b,c   Weidenmaier, Christopher ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Cecolabs UG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; TEICHOIC ACID;

ALANYLATION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL GENE; CHEMICAL REACTION; CONTROLLED STUDY; CROSS LINKING; DRY MASS; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MPRF GENE; NONHUMAN; SINGLE NUCLEOTIDE POLYMORPHISM; SURFACE CHARGE; TAGA GENE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CELL WALL; DAPTOMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PEPTIDOGLYCAN; PHENOTYPE; STAPHYLOCOCCAL INFECTIONS; TEICHOIC ACIDS;

BACTERIA (MICROORGANISMS); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS AUREUS;

EID: 84879047022     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067398     Document Type: Article

References (40)

1. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, et al. (2011) Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52: 285-292. doi:10.1093/cid/cir034. PubMed: 21217178.
2. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML, (2010) Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23: 99-139. doi:10.1128/CMR.00042-09. PubMed: 20065327.
3. Sakoulas G, Eliopoulos GM, Moellering RC Jr., Novick RP, Venkataraman L, et al. (2003) Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187: 929-938. doi:10.1086/368128. PubMed: 12660939.
4. Wootton M, MacGowan AP, Walsh TR, (2006) Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 50: 4195-4197. doi:10.1128/AAC.00678-06. PubMed: 17043121.
5. Boucher HW, Sakoulas G, (2007) Perspectives on Daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45: 601-608. doi:10.1086/520655. PubMed: 17682996.
6. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, et al. (2005) Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol 43: 5285-5287. doi:10.1128/JCM.43.10.5285-5287.2005. PubMed: 16207998.
7. Skiest DJ, (2006) Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 44: 655-656. doi:10.1128/JCM.44.2.655-656.2006. PubMed: 16455939.
8. Yang SJ, Kreiswirth BN, Sakoulas G, Yeaman MR, Xiong YQ, et al. (2009) Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus. J Infect Dis 200: 1916-1920. doi:10.1086/648473. PubMed: 19919306.
9. Yang SJ, Nast CC, Mishra NN, Yeaman MR, Fey PD, et al. (2010) Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms. Antimicrob Agents Chemother 54: 3079-3085. doi:10.1128/AAC.00122-10. PubMed: 20498310.
10. Yang SJ, Xiong YQ, Dunman PM, Schrenzel J, François P, et al. (2009) Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains. Antimicrob Agents Chemother 53: 2636-2637. doi:10.1128/AAC.01415-08. PubMed: 19289517.
11. Bayer AS, Schneider T, Sahl HG, (2013) Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci, 1277: 139-58. PubMed: 23215859.
12. Jones T, Yeaman MR, Sakoulas G, Yang SJ, Proctor RA, et al. (2008) Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52: 269-278. doi:10.1128/AAC.00719-07. PubMed: 17954690.
13. Mishra NN, Yang SJ, Sawa A, Rubio A, Nast CC, et al. (2009) Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 53: 2312-2318. doi:10.1128/AAC.01682-08. PubMed: 19332678.
14. Mishra NN, McKinnell J, Yeaman MR, Rubio A, Nast CC, et al. (2011) In vitro cross-resistance to daptomycin and host defense cationic antimicrobial peptides in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 55: 4012-4018. doi:10.1128/AAC.00223-11. PubMed: 21709105.
15. Julian K, Kosowska-Shick K, Whitener C, Roos M, Labischinski H, et al. (2007) Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob Agents Chemother 51: 3445-3448. doi:10.1128/AAC.00559-07. PubMed: 17620372.
16. Pillai SK, Gold HS, Sakoulas G, Wennersten C, Moellering RC Jr., et al. (2007) Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51: 2223-2225. doi:10.1128/AAC.00202-07. PubMed: 17404001.
17. Peschel A, Jack RW, Otto M, Collins LV, Staubitz P, et al. (2001) Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 193: 1067-1076. doi:10.1084/jem.193.9.1067. PubMed: 11342591.
18. Ernst CM, Peschel A, (2011) Broad-spectrum antimicrobial peptide resistance by MprF-mediated aminoacylation and flipping of phospholipids. Mol Microbiol 80: 290-299. doi:10.1111/j.1365-2958.2011.07576.x. PubMed: 21306448.
19. Mohedano ML, Overweg K, de la Fuente A, Reuter M, Altabe S, et al. (2005) Evidence that the essential response regulator YycF in Streptococcus pneumoniae modulates expression of fatty acid biosynthesis genes and alters membrane composition. J Bacteriol 187: 2357-2367. doi:10.1128/JB.187.7.2357-2367.2005. PubMed: 15774879.
20. Dubrac S, Bisicchia P, Devine KM, Msadek T, (2008) A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. Mol Microbiol 70: 1307-1322. doi:10.1111/j.1365-2958.2008.06483.x. PubMed: 19019149.
21. Bertsche U, Weidenmaier C, Kuehner D, Yang SJ, Baur S, et al. (2011) Correlation of Daptomycin-Resistance in a Clinical Staphylococcus aureus Strain with Increased Cell Wall Teichoic Acid Production and D-alanylation. Antimicrob Agents Chemother.
22. Ginsberg C, Zhang YH, Yuan Y, Walker S, (2006) In vitro reconstitution of two essential steps in wall teichoic acid biosynthesis. ACS Chem Biol 1: 25-28. doi:10.1021/cb0500041. PubMed: 17163636.
23. Xia G, Peschel A, (2008) Toward the pathway of S. aureus WTA biosynthesis. Chem Biol 15: 95-96. doi:10.1016/j.chembiol.2008.02.005. PubMed: 18291312.
24. Peschel A, Otto M, Jack RW, Kalbacher H, Jung G, et al. (1999) Inactivation of the dlt operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J Biol Chem 274: 8405-8410. doi:10.1074/jbc.274.13.8405. PubMed: 10085071.
25. Weidenmaier C, Kokai-Kun JF, Kristian SA, Chanturiya T, Kalbacher H, et al. (2004) Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 10: 243-245. doi:10.1038/nm991. PubMed: 14758355.
26. Kristian SA, Datta V, Weidenmaier C, Kansal R, Fedtke I, et al. (2005) D-alanylation of teichoic acids promotes group a streptococcus antimicrobial peptide resistance, neutrophil survival, and epithelial cell invasion. J Bacteriol 187: 6719-6725. doi:10.1128/JB.187.19.6719-6725.2005. PubMed: 16166534.
27. Peschel A, Ottenwälder B, Götz F, (1996) Inducible production and cellular location of the epidermin biosynthetic enzyme EpiB using an improved staphylococcal expression system. FEMS Microbiol Lett 137: 279-284. doi:10.1111/j.1574-6968.1996.tb08119.x. PubMed: 8998998.
28. Peschel A, Vuong C, Otto M, Götz F, (2000) The D-alanine residues of Staphylococcus aureus teichoic acids alter the susceptibility to vancomycin and the activity of autolytic enzymes. Antimicrob Agents Chemother 44: 2845-2847. doi:10.1128/AAC.44.10.2845-2847.2000. PubMed: 10991869.
29. de Jonge BL, Chang YS, Gage D, Tomasz A, (1992) Peptidoglycan composition of a highly methicillin-resistant Staphylococcus aureus strain. The role of penicillin binding protein 2A. J Biol Chem 267: 11248-11254.
30. Zhou X, Cegelski L, (2012) Nutrient-Dependent Structural Changes in S. aureus Peptidoglycan Revealed by Solid-State NMR Spectroscopy. Biochemistry 51: 8143-8153. doi:10.1021/bi3012115. PubMed: 22974326.
31. Camargo IL, Neoh HM, Cui L, Hiramatsu K, (2008) Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 52: 4289-4299. doi:10.1128/AAC.00417-08. PubMed: 18824611.
32. Cui L, Tominaga E, Neoh HM, Hiramatsu K, (2006) Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. Antimicrob Agents Chemother 50: 1079-1082. doi:10.1128/AAC.50.3.1079-1082.2006. PubMed: 16495273.
33. McAleese F, Wu SW, Sieradzki K, Dunman P, Murphy E, et al. (2006) Overexpression of genes of the cell wall stimulon in clinical isolates of Staphylococcus aureus exhibiting vancomycin-intermediate- S. aureus-type resistance to vancomycin. J Bacteriol 188: 1120-1133. doi:10.1128/JB.188.3.1120-1133.2006. PubMed: 16428416.
34. Muthaiyan A, Silverman JA, Jayaswal RK, Wilkinson BJ, (2008) Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization. Antimicrob Agents Chemother 52: 980-990. doi:10.1128/AAC.01121-07. PubMed: 18086846.
35. Boyle-Vavra S, Jones M, Gourley BL, Holmes M, Ruf R, et al. (2011) Comparative genome sequencing of an isogenic pair of USA800 clinical methicillin-resistant Staphylococcus aureus isolates obtained before and after daptomycin treatment failure. Antimicrob Agents Chemother 55: 2018-2025. doi:10.1128/AAC.01593-10. PubMed: 21343446.
36. Fischer A, Yang SJ, Bayer AS, Vaezzadeh AR, Herzig S, et al. (2011) Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approach. J Antimicrob Chemother 66: 1696-1711. doi:10.1093/jac/dkr195. PubMed: 21622973.
37. Göhring N, Fedtke I, Xia G, Jorge AM, Pinho MG, et al. (2011) New Role of the Disulfide Stress Effector YjbH in β-Lactam Susceptibility of Staphylococcus aureus. Antimicrob Agents Chemother 55: 5452-5458. PubMed: 21947404.
38. Strandén AM, Ehlert K, Labischinski H, Berger-Bächi B, (1997) Cell wall monoglycine cross-bridges and methicillin hypersusceptibility in a femAB null mutant of methicillin-resistant Staphylococcus aureus. J Bacteriol 179: 9-16. PubMed: 8981974.
39. Boneca IG, Xu N, Gage DA, de Jonge BL, Tomasz A, (1997) Structural characterization of an abnormally cross-linked muropeptide dimer that is accumulated in the peptidoglycan of methicillin- and cefotaxime-resistant mutants of Staphylococcus aureus. J Biol Chem 272: 29053-29059. doi:10.1074/jbc.272.46.29053. PubMed: 9360979.
40. de Jonge BL, Sidow T, Chang YS, Labischinski H, Berger-Bachi B, et al. (1993) Altered muropeptide composition in Staphylococcus aureus strains with an inactivated femA locus. J Bacteriol 175: 2779-2782. PubMed: 8478340.